Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(328)
•••
Post by moneywagonon Oct 06, 2022 10:27am
91 Views
Post# 35009212

BIOV WILL WE BEAT YESTERDAY'S VOLUME 1.3? CURRENTLY 900K

BIOV WILL WE BEAT YESTERDAY'S VOLUME 1.3? CURRENTLY 900K
C:BIOV - BioVaxys Technology Corp. - https://biovaxys.com
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
BIOV - C   1.0 0.22 · 0.23 6.0 0.23 +0.025 12.2 897.8 198 288 0.215  0.27  0.20 0.465  0.085 10:07:58 09:59 15 min RT 2¢
CSE - C 1.0 0.22 · 0.23 6.0 0.225 +0.02 9.8 477.8 105 161 0.215  0.26  0.20 0.465  0.085 10:07:57   15 min
NEO ATS - U   0.23 +0.025 12.2 252.5 57 63 0.22  0.26  0.205   10:07:58   15 min
Omega - O   0.225 +0.02 9.8 129.5 29 33 0.22  0.26  0.205   10:07:58   15 min
Chi-X - X   0.24 +0.035 17.1 2.0 0 2 0.22  0.24  0.22   09:52:05   15 min
CX2 - H   0.225 +0.02 9.8 32.5 7 14 0.24  0.27  0.225   10:07:58   15 min
CXD - D   0.205     0.4   1        Jul 04   15 min
TriAct - M   0.205     3.1 0 14            15 min

Close Prices Last 3 Months

Date Ex Sym Open High Low Close Chg Total Vol #Tr Bid Ask C-CSE U-NEO ATS A-Alpha O-Omega P-Pure X-Chi-X H-CX2 D-CXD L-LiquidNet M-TriAct I-Instinet Y-Lynx
2022-10-05 C BIOV 0.12 0.21 0.115 0.205 0.10 1,296,692 354 0.205 0.22 840,822 306,500   83,000   5,000 57,103     4,267    
2022-10-04 C BIOV 0.115 0.115 0.105 0.115 -0.005 30,353 20 0.11 0.12 24,500 3,000         1,500     425    
2022-10-03 C BIOV 0.12 0.12 0.10 0.12 0.005 78,858 30 0.115 0.12 59,308 17,000   2,500                
2022-09-30 C BIOV   0.115   0.115 0.125                  

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities